Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
This study is ongoing, but not recruiting participants.
University of California, Irvine
First Posted: March 23, 2011
Last Update Posted: December 8, 2016
Information provided by (Responsible Party):
John P. Fruehauf, University of California, Irvine